Peer-influenced content. Sources you trust. No registration required. This is HCN.
MedTech Dive
Dexcom’s innovative continuous glucose monitor is set to transform the management of type 2 diabetes for non-insulin users in the US, offering personalized insights to help them optimize their lifestyle choices while minimizing the need for insulin.
Endocrinology, Diabetes, Metabolism July 6th 2023
SingleCare
Explore how the age-old remedy of apple cider vinegar might offer modern benefits for men’s health, including weight management, blood sugar control, and cholesterol reduction.
All Specialties June 21st 2023
DentalReach
The invention of plant-based oral insulin, which provides a more secure and efficient substitute for insulin injections, marks a significant advancement in the management of diabetes. Investigate this ground-breaking strategy that could revolutionize accessibility to diabetes treatment worldwide.
Dentistry June 16th 2023
ACP Internist
The World Health Organization advises against nonsugar sweeteners for weight control, citing potential long-term risks such as type 2 diabetes and cardiovascular diseases. Instead, reducing free sugars and opting for natural sweetness sources is recommended to enhance dietary quality.
Endocrinology, Diabetes, Metabolism June 14th 2023
Diabetes Food Hub
The Diabetes Plate Method streamlines meal planning for diabetes management. Utilizing a 9-inch plate, it divides meal components into nonstarchy vegetables, lean proteins, and carbohydrates. An efficient tool for physicians to guide patient dietary habits effectively.
DDW News
Let’s delve into the groundbreaking application of endoscopic electroporation and semaglutide that’s changing the game in diabetes management. First off, the EMINENT study is unveiling a revolutionary approach in treating type 2 diabetes. This method combines endoscopic electroporation, known as ReCET, with the medication semaglutide. The main goal is to reduce or potentially eliminate the need for insulin, revolutionizing glycemic control. The innovative ReCET procedure employs electroporation to ablate the superficial layer of mucosa in the small intestine. Researchers hope that by rejuvenating the duodenal lining and employing a GLP-1 receptor agonist, they could address insulin resistance, the fundamental problem in type 2 diabetes. Interestingly, ReCET doesn’t use extreme temperatures to ablate intestinal tissue. Rather, it uses a pulsed electric field, yielding precise control and limited depth of penetration. This method disrupts the cellular membrane of the mucosa and superficial submucosa, triggering natural cell death within a day, thereby significantly minimizing the risk of complications. A single-arm pilot study conducted as part of EMINENT involved 14 patients with type 2 diabetes using long-acting basal insulin. All patients underwent the ReCET procedure and started on semaglutide two weeks later. Researchers noted the feasibility and safety of ReCET, with a 100% success […]
Endocrinology, Diabetes, Metabolism May 24th 2023